Ethyl pyruvate ameliorates monocrotaline-induced pulmonary arterial hypertension in rats

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 1, 2014, Pages 7-15

  Liu, Chuanzhen ^a   Fang, Changcun ^a   Cao, Guangqing ^a   Liu, Kai ^a   Wang, Biao ^a   Wan, Zhaojie ^b   Li, Sijie ^b   Wu, Shuming ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

ET 1; Ethyl pyruvate; IL 6; monocrotaline; pulmonary arterial hypertension; TNF

Indexed keywords

ENDOTHELIN 1; INTERLEUKIN 6; MONOCROTALINE; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ETHYL PYRUVATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; HYPERTENSION, PULMONARY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERTENSION, PULMONARY; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; MALE; MONOCROTALINE; PYRUVATES; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904265121     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000083     Document Type: Article

References (64)

1. Hessel MH, Steendijk P, den Adel B, et al. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol. 2006;291: H2424YH2430
2. Huisman AM, Vreugdenhil SA, van Paassen HC. Treatment of pulmonary arterial hypertension. N Engl J Med. 2005;352:308Y309;author reply 308Y309
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425Y1436
4. Martin KB, Klinger JR, Rounds SI. Pulmonary arterial hypertension: New insights and new hope. Respirology. 2006;11:6Y17
5. Raiesdana A, Loscalzo J. Pulmonary arterial hypertension. Ann Med. 2006;38:95Y110
6. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156Y163
7. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336: 111Y117
8. Varma SD, Hegde KR, Kovtun S. Oxidative damage to lens in culture: Reversibility by pyruvate and ethyl pyruvate. Ophthalmologica. 2006; 220:52Y57
9. Fink MP. Ethyl pyruvate: A novel anti-inflammatory agent. J Intern Med. 2007;261:349Y362
10. Fink MP. Ringer's ethyl pyruvate solution: A novel resuscitation fluid for the treatment of hemorrhagic shock and sepsis. J Trauma. 2003;54: S141YS143
11. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A. 2002;99:12351Y12356
12. Yang R, Gallo DJ, Baust JJ, et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol. 2002;283:G212YG221
13. Luan ZG, Ma XC, Zhang H, et al. Protective effect of ethyl pyruvate on pancreas injury in rats with severe acute pancreatitis. J Surg Res. 2013; 181:76Y84
14. Luan ZG, Zhang J, Yin XH, et al. Ethyl pyruvate significantly inhibits tumour necrosis factor a, interleukin 1b and high mobility group box 1 releasing and attenuates sodium taurocholate induced severe acute pancreatitis associated with acute lung injury. Clin Exp Immunol. 2013;172: 417Y426
15. Yang R, Uchiyama T, Alber SM, et al. Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit Care Med. 2004;32:1453Y1459
16. Wang LW, Wang LK, Chen H, et al. Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats. World J Gastroenterol. 2012; 18:5709Y5718
17. Su X, Wang H, Zhu L, et al. Ethyl pyruvate ameliorates intracerebral hemorrhage induced brain injury through anti-cell death and antiinflammatory mechanisms. Neuroscience. 2013
18. Shang GH, Lin D-J, Xiao W, et al. Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model. Respir Res. 2009;10:91
19. Kung CW, Lee YM, Cheng PY, et al. Ethyl pyruvate reduces acute lung injury via regulation of inos and ho-1 expression in endotoxemic rats. J Surg Res. 2011;167:e323Ye331
20. Epperly M, Jin S, Nie S, et al. Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation. Radiat Res. 2007;168: 552Y559
21. Alston TA. Postischemic treatment with ethyl pyruvate prevents adenosine triphosphate depletion, ameliorates inflammation, and decreases thrombosis in a murine model of hind-limb ischemia and reperfusion. J Trauma 2011; 70:103Y110
22. Cruz RJ Jr, Harada T, Sasatomi E, et al. Effects of ethyl pyruvate and other a-keto carboxylic acid derivatives in a rat model of multivisceral ischemia and reperfusion. J Surg Res. 2011;165:151Y157
23. Hu X, Cui B, Zhou X, et al. Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol Biol Rep. 2012;39:227Y231
24. Uchiyama T, Delude RL, Fink MP. Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med. 2003;29:2050Y2058
25. Kim HS, Cho IH, Kim JE, et al. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ros-dependent stat signaling in activated microglia. Free Radic Biol Med. 2008;45:950Y963
26. Park SY, Yi EY, Jung M, et al. Ethyl pyruvate, an anti-inflammatory agent, inhibits tumor angiogenesis through inhibition of the nf-kb signaling pathway. Cancer Lett. 2011;303:150Y154
27. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11:554Y559
28. Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type ii through a novel stat3YmicroRNA cluster 17/92 pathway. Circ Res. 2009;104: 1184Y1191
29. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104:236Y244
30. Fujita M, Mason RJ, Cool C, et al. Pulmonary hypertension in TNF-aoverexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol (1985). 2002;93:2162Y2170
31. Tsai BM, Lahm T, Morrell ED, et al. Ethyl pyruvate inhibits hypoxic pulmonary vasoconstriction and attenuates pulmonary artery cytokine expression. J Surg Res. 2008;145:130Y134
32. Hayashi Y, Hussa J, Lalich J. Cor pulmonale in rats. Lab Invest. 1967;16: 875
33. Everett AD, Le Cras TD, Xue C, et al. Enos expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol. 1998;274:L1058YL1065
34. Megalou AJ, Glava C, Oikonomidis DL, et al. Transforming growth factor-b inhibition attenuates pulmonary arterial hypertension in rats. Int J Clin Exp Med. 2010;3:332
35. Cacoub P, Dorent R, Maistre G, et al. Endothelin-1 in primary pulmonary hypertension and the eisenmenger syndrome. Am J Cardiol. 1993;71: 448Y450
36. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214Y221
37. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 1999;99:3266Y3271
38. Szczeklik J, Szczeklik A, Nizankowski R. Prostacyclin for pulmonary hypertension. Lancet. 1980;316:1076. (Pubitemid 11225358)
39. Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFa contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med. 2011;89:771Y783
40. Archer SL, Fang YH, Ryan JJ, et al. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ. 2013;3:144
41. Piao L, Sidhu VK, Fang YH, et al. Foxo1-mediated upregulation of pyruvate dehydrogenase kinase-4 (pdk4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: Therapeutic benefits of dichloroacetate. J Mol Med. 2013;91:333Y346
42. Piao L, Fang YH, Cadete VJ, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle. J Mol Med. 2010;88:47Y60
43. Kim JB, Yu YM, Kim SW, et al. Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious neuroprotection in the postischemic brain. Brain Res. 2005;1060:188Y192
44. Jasmin JF, Mercier I, Dupuis J, et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation. 2006;114:912Y920
45. Mathew R, Huang J, Shah M, et al. Disruption of endothelial-cell caveolin-1a/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation. 2004;110:1499Y1506
46. Tsutsumi Y, Makita T, Yamaguchi K, et al. Jtv-506, a new katp channel opener, relaxes pulmonary artery isolated from monocrotaline-treated pulmonary hypertensive rats. J Anesth. 2004;18:210Y215
47. Takahashi T, Kanda T, Sumino H, et al. Type v phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Res Exp Med. 1998; 197:319Y328
48. Calabrò P, Limongelli G, Maddaloni V, et al. Analysis of endothelin-1 and endothelin-1 receptor a gene polymorphisms in patients with pulmonary arterial hypertension. Intern Emerg Med. 2012;7:425Y430
49. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of etbreceptors. J Appl Physiol. 1996;81:1510Y1515
50. Giaid A, Polak JM, Gaitonde V, et al. Distribution of endothelin-like immunoreactivity and mrna in the developing and adult human lung. Am J Respir Cell Mol Biol. 1991;4:50Y58
51. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732Y1739
52. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?. Ann Intern Med. 1991;114:464Y469
53. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993;73:887Y897
54. Wong J, Reddy VM, Hendricks-Munoz K, et al. Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol. 1995;269:H1965YH1972
55. Hill NS, Warburton RR, Pietras L, et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol (1985). 1997;83:1209Y1215
56. Jasmin JF, Lucas M, Cernacek P, et al. Effectiveness of a nonselective eta/b and a selective eta antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation. 2001;103:314Y318
57. Prié S, Stewart DJ, Dupuis J. EndothelinA receptor blockade improves nitric oxideYmediated vasodilation in monocrotaline-induced pulmonary hypertension. Circulation. 1998;97:2169Y2174
58. Rondelet B, Kerbaul F, Motte S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation. 2003;107:1329Y1335
59. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049Y2056
60. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-a receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study. Chest. 2002;121:1860Y1868
61. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebocontrolled study. Lancet. 2001;358:1119Y1123
62. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896Y903
63. Sandoval J, Torbicki A, Souza R, et al. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther. 2012;25:33Y39
64. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest. 2003;124:247Y254